Close

Eli Lilly & Co. (LLY) Will Extend Evacetrapib Phase 3 by Six Months

February 19, 2015 8:02 AM EST Send to a Friend
Eli Lilly & Co. (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login